Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Down – Should You Sell?

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $25.00, but opened at $23.85. Centessa Pharmaceuticals shares last traded at $23.7450, with a volume of 3,031 shares.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Truist Financial upped their price target on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the stock a “buy” rating in a research note on Thursday, January 29th. Wall Street Zen raised Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, October 27th. Wells Fargo & Company increased their price objective on shares of Centessa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Oppenheimer raised their target price on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an “outperform” rating in a report on Wednesday, December 10th. Finally, Guggenheim lifted their price target on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $38.50.

Centessa Pharmaceuticals Stock Down 0.2%

The firm has a market capitalization of $3.16 billion, a PE ratio of -12.84 and a beta of 1.56. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. The business’s 50 day simple moving average is $25.11 and its 200 day simple moving average is $22.72.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). On average, equities research analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Mario Alberto Accardi sold 10,000 shares of the stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $30.00, for a total value of $300,000.00. Following the transaction, the insider owned 178,801 shares of the company’s stock, valued at $5,364,030. This represents a 5.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Iqbal J. Hussain sold 38,951 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total value of $979,617.65. Following the transaction, the insider owned 57,645 shares in the company, valued at $1,449,771.75. The trade was a 40.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 89,961 shares of company stock worth $2,344,878 in the last three months. Corporate insiders own 7.09% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several institutional investors have recently made changes to their positions in CNTA. TD Waterhouse Canada Inc. purchased a new stake in shares of Centessa Pharmaceuticals in the 4th quarter worth approximately $25,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Centessa Pharmaceuticals by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock valued at $117,000 after purchasing an additional 979 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Centessa Pharmaceuticals during the second quarter worth $218,000. DNB Asset Management AS acquired a new stake in Centessa Pharmaceuticals during the 3rd quarter worth about $218,000. Finally, Sigma Planning Corp acquired a new stake in shares of Centessa Pharmaceuticals during the fourth quarter worth about $225,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.